Lam Siu Wing 林兆荣
Companies 任职公司
| Company 公司 | Industry 行业 | Role 职务 | Since 起始 | Grade 评级 |
|---|---|---|---|---|
| Adisseo 安迪苏 | Chemical Products | Independent Director | 19 Sep 2024 | C |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical 复旦张江 | Chemical Pharmaceuticals | Independent Non-executive Director | 28 May 2026 | C |
Biography 简历
林兆荣,生于1960年,中国香港,澳洲麦觉理大学经济学会计专业学士,澳洲新南威尔士大学商务学金融专业硕士,香港会计师公会资深会员,澳洲和新西兰特许会计师公会资深会员。曾在澳洲(5年)、香港(6年)及中国(25年)工作,从事审计及商务咨询项目超过30年,在会计、企业咨询等领域有丰富的经验。2004年至2020年任普华永道中天会计师事务所(特殊普通合伙)及罗兵咸永道会计师事务所合伙人。林先生也曾于多间审计公司任职,包括香港毕马威会计师事务所(自1991年9月至1992年2月)、Horwath Australia(自1987年8月至1991年8月)及新南威尔士州审计长办公室(自1987年3月至1987年7月)。自2022年6月起,任上海格派鎳鈷材料股份有限公司(未上市)的独立董事;自2023年5月起,任上海复旦张江生物医药股份有限公司(于香港联交所上市,股票代码:01349;于上海证券交易所上市,证券代码:688505)独立董事;自2023年7月起,任苏州贝康医疗股份有限公司(于香港联交所上市,股票代码:02170)的独立董事;自2023年10月担任新疆新鑫矿业股份有限公司(于香港联交所上市,股票代码:03833)的联席公司秘书;自2024年5月起,任西安经发物业股份有限公司(于香港联交所上市,股票代码:01354)的独立董事;自2025年6月起,任齐屹科技(开曼)有限公司(于香港联交所上市,股票代码01739)的独立董事;自2025年6月起,任上海壁仞科技股份有限公司(于香港联交所上市,股票代码06082)独立董事。自2024年9月起任本公司独立董事及审计、风险及合规委员会主任委员。
English Translation 英文译文 · Organisation Names in Chinese 机构名称保留中文Lin Zhaorong, born in 1960, Hong Kong, China, Bachelor of 澳洲麦觉理大学经济学会 Accounting, 澳洲新南威尔士大学 Business School Finance Master, Senior Member of the Hong Kong Institute of Certified Public Accountants, Senior Member of the Chartered Institute of Management Accountants (UK) and New Zealand. He has worked in Australia (5 years), Hong Kong (6 years) and China (25 years), engaged in auditing and business consulting projects for over 30 years, with extensive experience in accounting, corporate consulting and other fields. From 2004 to 2020, he was a partner of 普华永道中天会计师事务所 (Special Partnership) and 罗兵咸永道会计师事务所. Mr. Lin has also worked for 多间审计公司, 包括香港毕马威会计师事务所 (from September 1991 to February 1992), Horwath Australia (from August 1987 to August 1991) and the Office of the Auditor-General of New South Wales (from March 1987 to July 1987). Since June 2022, he has been an Independent Director of 上海格派鎳鈷材料股份有限公司 (unlisted); Since May 2023, he has been an Independent Director of 上海复旦张江生物医药股份有限公司 (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical) (listed on Hong Kong 联交所 with stock code: 01349; listed on 上海证券交易所 with securities code: 688505); Since July 2023, he has been an Independent Director of 苏州贝康医疗股份有限公司 (listed on Hong Kong 联交所 with stock code: 02170); Since October 2023, he has been the 联席公司 Secretary of 新疆新鑫矿业股份有限公司 (listed on Hong Kong 联交所 with stock code: 03833); Since May 2024, he has been an Independent Director of 西安经发物业股份有限公司 (listed on Hong Kong 联交所 with stock code: 01354); From June 2025, he serves as an Independent Director of 齐屹科技(开曼)有限公司 (listed on the Hong Kong 联交所, stock code 01739); From June 2025, he serves as an Independent Director of 上海壁仞科技股份有限公司 (listed on the Hong Kong 联交所, stock code 06082). Since September 2024, he has been an Independent Director of the Company and Chairman of the Audit, Risk and Compliance Committee.